P-209 - MODEL-INFORMED CLINICAL PHARMACOLOGY (CP) PROFILE OF A NOVEL FIXED-DOSE COMBINATION (FDC) OF RELATLIMAB AND NIVOLUMAB IN PATIENTS WITH SOLID TUMORS.
Y. Zhao, Z. Hu, R. Suryawanshi, P. Statkevich, A. Roy, A. Bello, S. Suryawanshi; Bristol Myers Squibb, Princeton, NJ, USA.
.png)